BIOMAT Database Logo BIOMAT Database Logo

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. 1999

J B Smaill, and B D Palmer, and G W Rewcastle, and W A Denny, and D J McNamara, and E M Dobrusin, and A J Bridges, and H Zhou, and H D Showalter, and R T Winters, and W R Leopold, and D W Fry, and J M Nelson, and V Slintak, and W L Elliot, and B J Roberts, and P W Vincent, and S J Patmore
Auckland Cancer Society Research Centre, Faculty of Medicine and Health Science, The University of Auckland, Private Bag 92019, Auckland, New Zealand.

A series of 6- and 7-acrylamide derivatives of the 4-(phenylamino)quinazoline and -pyridopyrimidine classes of epidermal growth factor receptor (EGFR) inhibitors were prepared from the corresponding amino compounds by reaction with either acryloyl chloride/base or acrylic acid/1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. All of the 6-acrylamides, but only the parent quinazoline 7-acrylamide, were irreversible inhibitors of the isolated enzyme, confirming that the former are better-positioned, when bound to the enzyme, to react with the critical cysteine-773. Quinazoline, pyrido[3,4-d]pyrimidine, and pyrido[3,2-d]pyrimidine 6-acrylamides were all irreversible inhibitors and showed similar high potencies in the enzyme assay (likely due to titration of the available enzyme). However the pyrido[3,2-d]pyrimidine analogues were 2-6-fold less potent than the others in a cellular autophosphorylation assay for EGFR in A431 cells. The quinazolines were generally less potent overall toward inhibition of heregulin-stimulated autophosphorylation of erbB2 (in MDA-MB-453-cells), whereas the pyridopyrimidines were equipotent. Selected compounds were evaluated in A431 epidermoid and H125 non-small-cell lung cancer human tumor xenografts. The compounds showed better activity when given orally than intraperitoneally. All showed significant tumor growth inhibition (stasis) over a dose range. The poor aqueous solubility of the compounds was a drawback, requiring formulation as fine particulate emulsions.

UI MeSH Term Description Entries
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J B Smaill, and B D Palmer, and G W Rewcastle, and W A Denny, and D J McNamara, and E M Dobrusin, and A J Bridges, and H Zhou, and H D Showalter, and R T Winters, and W R Leopold, and D W Fry, and J M Nelson, and V Slintak, and W L Elliot, and B J Roberts, and P W Vincent, and S J Patmore
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
April 2000, Journal of medicinal chemistry,
J B Smaill, and B D Palmer, and G W Rewcastle, and W A Denny, and D J McNamara, and E M Dobrusin, and A J Bridges, and H Zhou, and H D Showalter, and R T Winters, and W R Leopold, and D W Fry, and J M Nelson, and V Slintak, and W L Elliot, and B J Roberts, and P W Vincent, and S J Patmore
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido
August 2000, Journal of medicinal chemistry,
J B Smaill, and B D Palmer, and G W Rewcastle, and W A Denny, and D J McNamara, and E M Dobrusin, and A J Bridges, and H Zhou, and H D Showalter, and R T Winters, and W R Leopold, and D W Fry, and J M Nelson, and V Slintak, and W L Elliot, and B J Roberts, and P W Vincent, and S J Patmore
Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.
April 1996, Journal of medicinal chemistry,
J B Smaill, and B D Palmer, and G W Rewcastle, and W A Denny, and D J McNamara, and E M Dobrusin, and A J Bridges, and H Zhou, and H D Showalter, and R T Winters, and W R Leopold, and D W Fry, and J M Nelson, and V Slintak, and W L Elliot, and B J Roberts, and P W Vincent, and S J Patmore
Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
February 1996, Journal of medicinal chemistry,
J B Smaill, and B D Palmer, and G W Rewcastle, and W A Denny, and D J McNamara, and E M Dobrusin, and A J Bridges, and H Zhou, and H D Showalter, and R T Winters, and W R Leopold, and D W Fry, and J M Nelson, and V Slintak, and W L Elliot, and B J Roberts, and P W Vincent, and S J Patmore
Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
September 1995, Journal of medicinal chemistry,
J B Smaill, and B D Palmer, and G W Rewcastle, and W A Denny, and D J McNamara, and E M Dobrusin, and A J Bridges, and H Zhou, and H D Showalter, and R T Winters, and W R Leopold, and D W Fry, and J M Nelson, and V Slintak, and W L Elliot, and B J Roberts, and P W Vincent, and S J Patmore
Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
February 2001, Journal of medicinal chemistry,
J B Smaill, and B D Palmer, and G W Rewcastle, and W A Denny, and D J McNamara, and E M Dobrusin, and A J Bridges, and H Zhou, and H D Showalter, and R T Winters, and W R Leopold, and D W Fry, and J M Nelson, and V Slintak, and W L Elliot, and B J Roberts, and P W Vincent, and S J Patmore
Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.
September 1995, Journal of medicinal chemistry,
J B Smaill, and B D Palmer, and G W Rewcastle, and W A Denny, and D J McNamara, and E M Dobrusin, and A J Bridges, and H Zhou, and H D Showalter, and R T Winters, and W R Leopold, and D W Fry, and J M Nelson, and V Slintak, and W L Elliot, and B J Roberts, and P W Vincent, and S J Patmore
4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
June 1996, Journal of medicinal chemistry,
J B Smaill, and B D Palmer, and G W Rewcastle, and W A Denny, and D J McNamara, and E M Dobrusin, and A J Bridges, and H Zhou, and H D Showalter, and R T Winters, and W R Leopold, and D W Fry, and J M Nelson, and V Slintak, and W L Elliot, and B J Roberts, and P W Vincent, and S J Patmore
Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
June 1997, Journal of medicinal chemistry,
J B Smaill, and B D Palmer, and G W Rewcastle, and W A Denny, and D J McNamara, and E M Dobrusin, and A J Bridges, and H Zhou, and H D Showalter, and R T Winters, and W R Leopold, and D W Fry, and J M Nelson, and V Slintak, and W L Elliot, and B J Roberts, and P W Vincent, and S J Patmore
Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold.
July 2018, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!